Citigroup has initiated coverage on Roivant Sciences Ltd (ROIV) with a Buy rating as of September 1, 2025. The current price stands at $20.30.
Roivant Sciences, a biotechnology company based in Great Britain, focuses on developing transformative medicines. Its pipeline includes brepocitinib, a small molecule inhibitor of TYK2 and JAK1 aimed at treating dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. Other notable assets include IMVT-1402 and batoclimab, monoclonal antibodies targeting FcRn for various autoimmune conditions, and mosliciguat, an inhaled sGC activator for pulmonary hypertension.
With a market capitalization of $14.3 billion, Roivant reported an earnings per share (EPS) of -0.55 for the trailing twelve months (TTM). The company is set to announce its upcoming earnings on November 10, 2025, with EPS estimated at -0.34 and revenue expected to reach $7.1 million.
Analyst consensus indicates a Buy rating, with 7 Strong Buy, 9 Buy, and 2 Hold ratings among 18 analysts. Citigroup's initiation underscores a growing interest in Roivant's innovative pipeline and potential market impact.